PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/NTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk. Upon completion of this activity, participants will be able to: Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke, Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke, Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed, Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF.

Go online to PeerView.com/GVC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses how to effectively diagnose and assess atopic dermatitis, common comorbidities, international treatment guidelines, and optimal treatment strategies, including phosphodiesterase-4 and interleukin-4/-13 inhibitors. Upon completion of this activity, participants should be better able to: Recognize the multidimensional burden and unmet needs associated with atopic dermatitis (AD), Employ evidence-based strategies to determine disease impact and guide treatment decisions in individual patients with AD, Assess clinical data on new and emerging treatment options for atopic dermatitis, Develop individualized treatment plans for adults, adolescents, and children with atopic dermatitis based on current recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life.

Go online to PeerView.com/MYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts on severe asthma discuss how to identify and diagnose patients with this condition and how novel treatments are improving patient outcomes. A patient joins the discussion to share his unique experience with severe asthma and how biologic therapy has improved his quality of life. Upon completion of this activity, participants should be better able to: Diagnose and evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapy, Employ evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma, Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma.

Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.

Go online to PeerView.com/CBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist and certified diabetes educator discusses current and emerging treatment options for severe hypoglycemia. Upon completion of this activity, participants should be better able to: Recognize the role of glucagon for the treatment of severe hypoglycemia in patients with diabetes, Teach individuals outside of the hospital setting how and when to use glucagon to treat severe hypoglycemia, Evaluate the efficacy, safety, and ease of use of current and emerging glucagon rescue treatments for severe hypoglycemia

Go online to PeerView.com/UHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses the impact of dry eye disease and current and emerging treatment approaches for patients with dry eye disease. Upon completion of this activity, participants should be better able to: Recognize the impact of dry eye on the quality of life of patients, particularly if left untreated, Identify patients with dry eye according to signs, symptoms, and the latest diagnostic criteria, Summarize the latest clinical data on efficacy and safety of novel and emerging therapies for dry eye, Develop treatment plans for patients with dry eye according to disease severity and the latest clinical evidence of available therapeutic agents

Go online to PeerView.com/GZX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in hepatology discusses current and emerging strategies to diagnose, treat, and manage patients with nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Correctly diagnose and stage nonalcoholic fatty liver disease (NAFLD), distinguishing the subset of patients with NASH for disease monitoring and prognostication, Apply best practices in the management of patients with NASH based on evolving data on lifestyle modification and medical treatment, Evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH

Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs

Go online to PeerView.com/NNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hospital and vascular medicine discusses how real-world data enhance the data from randomized clinical trials on direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) and offers insight on applying evidence from both real-world studies and randomized clinical trials to improve patient care. Upon completion of this activity, participants will be able to: Identify the role of real-world data and evidence in augmenting the efficacy and safety data that have been collected as part of clinical trials for stroke prevention among patients with NVAF, Compare and contrast evidence collected to date from real-world studies with data reported from clinical trials of DOACs to prevent stroke among patients with NVAF, Apply evidence from real-world studies and clinical trials of DOACs in patients with NVAF

Go online to PeerView.com/GZS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gastrointestinal oncology provides an update on targeted therapies for patients with biliary tract cancers. Upon completion of this activity, participants should be better able to: Review the rationale of newly discovered targets, such as multikinase tumor pathways, NTRK gene fusions, and FGFR translocations, for biliary tract cancers, Appraise emerging efficacy and safety evidence on the use of novel targeted agents, including multikinase, TRK, and FGFR inhibitors, in patients with biliary tract cancers, Incorporate novel targeted agents safely and effectively into treatment plans for biliary tract cancers, including in the context of a clinical trial